Literature DB >> 21631239

Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes.

Yvonne W Cheng1, Judith H Chung, Ingrid Block-Kurbisch, Maribeth Inturrisi, Aaron B Caughey.   

Abstract

OBJECTIVE: To examine perinatal outcomes in women with gestational diabetes mellitus treated with glyburide compared to insulin injections. STUDY
DESIGN: This is a retrospective cohort study of women diagnosed with gestational diabetes mellitus (GDM) who required pharmaceutical therapy and were enrolled in the Sweet Success California Diabetes and Pregnancy Program between 2001 and 2004, a California state-wide program. Women managed with glyburide were compared to women treated with insulin injections. Perinatal outcomes were compared using chi-square test and multivariable logistic regression models; statistical significance was indicated by p < 0.05 and 95% confidence intervals (CI).
RESULTS: Among the 10,682 women with GDM who required medical therapy and met study criteria, 2073 (19.4%) received glyburide and 8609 (80.6%) received subcutaneous insulin injections. Compared to insulin therapy and controlling for confounders, oral hypoglycemic treatment was associated with increased risk of birthweight >4000 g (aOR = 1.29; 95% CI [1.03-1.64]), and admission to the intensive care nursery (aOR = 1.46 [1.07-2.00]).
CONCLUSION: Neonates born to women with gestational diabetes managed on glyburide, and were more likely to be macrosomic and to be admitted to the intensive care unit compared to those treated with insulin injections. These findings should be examined in a large, prospective trial.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631239      PMCID: PMC3443974          DOI: 10.3109/14767058.2011.580402

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  19 in total

1.  Gestational diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro.

Authors:  I W Smoak; T W Sadler
Journal:  Am J Obstet Gynecol       Date:  1990-08       Impact factor: 8.661

3.  Insignificant transfer of glyburide occurs across the human placenta.

Authors:  B D Elliott; O Langer; S Schenker; R F Johnson
Journal:  Am J Obstet Gynecol       Date:  1991-10       Impact factor: 8.661

4.  Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy.

Authors:  M L Kemball; C McIver; R D Milner; C H Nourse; D Schiff; J R Tiernan
Journal:  Arch Dis Child       Date:  1970-10       Impact factor: 3.791

5.  Fetal growth and perinatal viability in California.

Authors:  R L Williams; R K Creasy; G C Cunningham; W E Hawes; F D Norris; M Tashiro
Journal:  Obstet Gynecol       Date:  1982-05       Impact factor: 7.661

6.  Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population.

Authors:  B M Casey; M J Lucas; D D Mcintire; K J Leveno
Journal:  Obstet Gynecol       Date:  1997-12       Impact factor: 7.661

7.  A comparison of glyburide and insulin in women with gestational diabetes mellitus.

Authors:  O Langer; D L Conway; M D Berkus; E M Xenakis; O Gonzales
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

8.  Growth graphs for the clinical assessment of infants of varying gestational age.

Authors:  S G Babson; G I Benda
Journal:  J Pediatr       Date:  1976-11       Impact factor: 4.406

9.  Management of diabetes mellitus by obstetrician-gynecologists.

Authors:  Steven G Gabbe; Rebecca Pratt Gregory; Michael L Power; Sterling B Williams; Jay Schulkin
Journal:  Obstet Gynecol       Date:  2004-06       Impact factor: 7.661

10.  Metformin versus insulin for the treatment of gestational diabetes.

Authors:  Janet A Rowan; William M Hague; Wanzhen Gao; Malcolm R Battin; M Peter Moore
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

View more
  16 in total

Review 1.  Oral Agents for the Treatment of Gestational Diabetes.

Authors:  Matthew M Finneran; Mark B Landon
Journal:  Curr Diab Rep       Date:  2018-09-28       Impact factor: 4.810

Review 2.  Changing trends in management of gestational diabetes mellitus.

Authors:  Gunasekaran Kala Poomalar
Journal:  World J Diabetes       Date:  2015-03-15

Review 3.  Using oral agents to manage gestational diabetes: what have we learned?

Authors:  Elizabeth Buschur; Florence Brown; Jennifer Wyckoff
Journal:  Curr Diab Rep       Date:  2015-02       Impact factor: 4.810

Review 4.  The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy.

Authors:  Rachel A Blair; Emily A Rosenberg; Nadine E Palermo
Journal:  Curr Diab Rep       Date:  2019-12-06       Impact factor: 4.810

Review 5.  Safety considerations with pharmacological treatment of gestational diabetes mellitus.

Authors:  David Simmons
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

Review 6.  Pharmacological Management of Gestational Diabetes Mellitus.

Authors:  Riki Bergel; Eran Hadar; Yoel Toledano; Moshe Hod
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

7.  Review of metformin and glyburide in the management of gestational diabetes.

Authors:  Dana G Carroll; Kristi W Kelley
Journal:  Pharm Pract (Granada)       Date:  2014-03-15

Review 8.  Oral hypoglycemic agents: do the ends justify the means?

Authors:  Oded Langer
Journal:  Matern Health Neonatol Perinatol       Date:  2015-08-05

9.  The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity.

Authors:  Cigdem Tosun; Michael T Koltz; David B Kurland; Hina Ijaz; Melda Gurakar; Gary Schwartzbauer; Turhan Coksaygan; Svetlana Ivanova; Volodymyr Gerzanich; J Marc Simard
Journal:  Brain Sci       Date:  2013-03-07

Review 10.  A review of current treatment strategies for gestational diabetes mellitus.

Authors:  Kristi W Kelley; Dana G Carroll; Allison Meyer
Journal:  Drugs Context       Date:  2015-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.